Skip to main content

Featured

How to Pay Less Tax in Ontario in 2026 — A Complete Guide for Canadians

             Published: April 2026 | Reading time: 10 min | Category: Tax Savings, Personal Finance If you live in Ontario, you already know the tax bite is real. Between federal and provincial income tax, you could be handing over 43% or more of every extra dollar you earn. The good news? The Canadian tax system is loaded with legal ways to keep more of your money — and most people aren't using all of them. This guide covers every major strategy available to Ontario residents in 2026, from basic deductions to advanced moves that most people miss. Whether you're employed, self-employed, or earning investment income, there's something here for you. Why Ontario Residents Pay More Tax Than Most Canadians Ontario's combined federal and provincial marginal tax rates are among the highest in Canada. Here's what you're actually paying depending on your income in 2026: Taxable Income Combined Federal + Ontario Rate Up to $51,446 ~20.0...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment